LeadIQ logo
Learn more at LeadIQ.com

Insights

Cutting-Edge Immunotherapies Elicio Therapeutics is pioneering novel lymph node-targeted immunotherapies for aggressive cancers, leveraging AMP technology, which presents a significant opportunity for collaboration with hospitals and oncology centers seeking innovative treatment options.

Expanding R&D Pipeline With a pipeline including off-the-shelf therapeutic cancer vaccines targeting specific mutations, such as mKRAS, BRAF-driven, and p53 hotspot mutations, Elicio Therapeutics offers a range of solutions that can be positioned as essential tools in the fight against diverse types of cancer.

Strong Financial Backing With recent successful public offerings, grants, and private placement financing totaling over $24 million, Elicio Therapeutics' growing financial stability provides an opportunity for investors looking to partner with a promising biotechnology company with a focus on cancer research.

Market Visibility and Credibility Having received funding, advancements, and funding for studies as reported by respected platforms like Biospace, Investing.com, and others, Elicio Therapeutics' market presence offers sales partnerships the advantage of leveraging the company's credibility and reputation in the industry.

Addressing Unmet Medical Needs By developing vaccines like ELI-002 2P that target specific mutations and receiving grants to advance such research, Elicio Therapeutics presents a compelling opportunity for sales teams to engage healthcare providers looking to adopt cutting-edge approaches to address unmet medical needs in cancer treatment.

Similar companies to Elicio Therapeutics

Elicio Therapeutics Tech Stack

Elicio Therapeutics uses 8 technology products and services including MySQL, Google Font API, Swiper, and more. Explore Elicio Therapeutics's tech stack below.

  • MySQL
    Database
  • Google Font API
    Font Scripts
  • Swiper
    Javascript Libraries
  • RSS
    Miscellaneous
  • Priority Hints
    Performance
  • PHP
    Programming Languages
  • Yoast SEO
    Search Engines
  • Astra
    Web Platform Extensions

Media & News

Elicio Therapeutics's Email Address Formats

Elicio Therapeutics uses at least 1 format(s):
Elicio Therapeutics Email FormatsExamplePercentage
First.Last@elicio.comJohn.Doe@elicio.com
49%
Last@elicio.comDoe@elicio.com
1%
First.Last@elicio.comJohn.Doe@elicio.com
49%
Last@elicio.comDoe@elicio.com
1%

Frequently Asked Questions

Where is Elicio Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Elicio Therapeutics's main headquarters is located at 451 D Street 501 Boston, Massachusetts 02210 US. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is Elicio Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Elicio Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Elicio Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Elicio Therapeutics is a publicly traded company; the company's stock symbol is ELTX.

What is Elicio Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Elicio Therapeutics's official website is elicio.com and has social profiles on LinkedIn.

How much revenue does Elicio Therapeutics generate?

Minus sign iconPlus sign icon
As of September 2024, Elicio Therapeutics's annual revenue reached $3.8M.

What is Elicio Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Elicio Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Elicio Therapeutics have currently?

Minus sign iconPlus sign icon
As of September 2024, Elicio Therapeutics has approximately 38 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Scientific Officer: P. C. D.Chief Financial Officer: B. P.Chief Business Officer: A. M.. Explore Elicio Therapeutics's employee directory with LeadIQ.

What industry does Elicio Therapeutics belong to?

Minus sign iconPlus sign icon
Elicio Therapeutics operates in the Biotechnology Research industry.

What technology does Elicio Therapeutics use?

Minus sign iconPlus sign icon
Elicio Therapeutics's tech stack includes MySQLGoogle Font APISwiperRSSPriority HintsPHPYoast SEOAstra.

What is Elicio Therapeutics's email format?

Minus sign iconPlus sign icon
Elicio Therapeutics's email format typically follows the pattern of . Find more Elicio Therapeutics email formats with LeadIQ.

How much funding has Elicio Therapeutics raised to date?

Minus sign iconPlus sign icon
As of September 2024, Elicio Therapeutics has raised $20M in funding. The last funding round occurred on Aug 12, 2024 for $20M.
Elicio Therapeutics

Elicio Therapeutics

Biotechnology ResearchMassachusetts, United States11-50 Employees

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with the Amphiphile (“AMP”) technology, which allows for therapeutic payloads to be delivered directly to the lymph nodes, with the goal of enhancing the immune system’s cancer-fighting capabilities. By targeting cancer immunotherapies to the core of the immune response, AMP aims to optimize the lymph nodes’ natural ability to educate, activate and amplify cancer-specific T cells, which are essential for recognizing and eliminating tumor cells. Engineered to synchronize immunity in these highly potent sites, AMP is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. The Company’s R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and ELI-008 (targeting BRAF-driven cancers and p53 hotspot mutations, respectively). For more information, please visit www.elicio.com. 

Section iconCompany Overview

Headquarters
451 D Street 501 Boston, Massachusetts 02210 US
Phone number
Website
elicio.com
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
ELTX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
11-50

Section iconFunding & Financials

  • $20M

    Elicio Therapeutics has raised a total of $20M of funding over 17 rounds. Their latest funding round was raised on Aug 12, 2024 in the amount of $20M.

  • $10M

    Elicio Therapeutics's revenue is in the range of $10M

Section iconFunding & Financials

  • $20M

    Elicio Therapeutics has raised a total of $20M of funding over 17 rounds. Their latest funding round was raised on Aug 12, 2024 in the amount of $20M.

  • $10M

    Elicio Therapeutics's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.